/** Note: User asked for blogpostSummary as Markdown MDX, but the required response format is JSON-only. Providing the markdown inside this JSON string field as requested by schema. */

Neuland Laboratories Q4 FY26: A CMS-led spike and a long-term bet on peptides

Neuland Laboratories ended Q4 FY26 with a sharp jump in reported performance, while repeatedly cautioning investors about the inherent lumpiness of a CDMO-heavy model. Standalone total income in Q4 FY26 rose to 788.7 crore versus 335.8 crore in Q4 FY25, with EBITDA at 319.4 crore and PAT at 212.5 crore. EBITDA margin expanded to 40.5% in the quarter. Management described this margin as exceptional, driven by record revenue in the quarter and the uneven timing of shipments.

For FY26, the company reported total income of 2,053.1 crore (37.1% YoY growth), EBITDA of 603.4 crore (29.4% margin), and PAT of 363.1 crore (17.7% margin). Management attributed the year’s step-up largely to the scale-up of key molecules in its CMS business and operating leverage.

What drove the quarter: CMS scale and shipment timing

In management commentary and the earnings call, the central driver for Q4 was CMS revenue from commercial molecules. The company also noted growth in new project orders expected to be delivered over the current and next financial year. The quarterly segment mix shows this clearly. CMS contributed 68% of revenue in Q4 FY26, rising from 34% in Q4 FY25.

The CFO added that exchange rates were a tailwind in Q4 because a large part of shipments occurred as the rupee depreciated. He also noted that freight costs rose toward the end of the quarter due to conflict-related disruption, but supply continuity was maintained.

Financial summary (Standalone)

Segment mix: CMS dominates, GDS remains softer

The company’s disclosed revenue mix highlights a decisive tilt toward CMS.

• Q4 FY26 segment revenue shares: Prime 18%, Specialty 8%, CMS 68%, Others 6%
• FY26 segment revenue shares: Prime 23%, Specialty 11%, CMS 61%, Others 6%

Management noted that GDS performance was softer in FY26. Within GDS, Ezetimibe and Mirtazapine were cited as key molecules in Prime, with Ezetimibe expected to drive growth. Specialty was described as subdued due to Paliperidone, with revenue driven by Apixaban, Donepezil and Aripiprazole Sterile. The company filed two new DMFs in FY26: Vonoprazan and Edoxaban.

A key takeaway from the operating metrics section is concentration. For Q4 FY26, CMS top 5 customers were 92% and top 10 customers were 100% of CMS revenue. CMS top 5 products were 94% and top 10 products were 99%. Management explained that the CMS business caters to innovator customers on an exclusive basis, which structurally concentrates customer exposure.

Cash flow and balance sheet: profitable, but cash conversion needs work

While net debt stayed negative, cash conversion was weaker in FY26. The CFO said FY26 free cash flow was negative 49.4 crore, driven primarily by higher working capital and increased capital cash outflows. Capex cash outflow for FY26 was 397.1 crore.

Working capital days were 137 in Q4 FY26 versus 107 in Q4 FY25, driven by higher inventories and receivables. Management said working capital should normalize in FY27 and emphasized actions around collections, inventory normalization and tighter operating controls. The CFO also pointed to cost and process improvement initiatives across the organization, including procurement efficiency and stronger cost governance.

On the balance sheet, the presentation reported net debt of negative 156.8 crore at FY26 end. It also showed shareholder funds at 1,865.9 crore and tangible assets including CWIP at 1,002.9 crore. ROCE for FY26 was 26.1%.

Strategy and capex: peptides and R and D as the next platform

Management’s strategic framing focused on building capabilities beyond the current CMS pipeline. Two investments were repeatedly highlighted.

First, peptides. The CEO described the peptide investment as a move into a more differentiated space, expanding from peptide fragments to peptide APIs. On the earnings call, management said there are 8 to 10 peptide programs in the development pipeline, while clarifying that some publicly discussed peptide programs are early stage and should not be assumed to generate near- or mid-term revenue.

Second, R and D. The presentation described a new state-of-the-art R and D center in Hyderabad’s Genome Valley spanning 140,000 square feet. The CEO positioned this as more than capacity addition, aimed at strengthening technical depth and the ability to support complex programs from early development through commercialization.

Management also addressed the market context. The presentation cited an external view that the peptide API market could grow from 6 billion in 2025 to 14 billion by 2030, implying an 18.5% CAGR. Management positioned peptides as an attractive CDMO opportunity, especially given GLP-1 driven demand.

Management tone: lumpiness acknowledged, long horizon emphasized

A consistent thread in the call was the insistence on evaluating performance over a longer cycle. Management stated that quarterly performance can be uneven and that even full-year outcomes can deviate because revenue timing does not align neatly with financial year boundaries.

On growth outlook, the CEO said there is good visibility for the next 2 to 3 years driven by the existing pipeline, but growth is expected to remain lumpy. When asked about prior commentary around 18% to 20% CAGR, management said it is a fair assumption over time, not necessarily linear.

They also acknowledged that ROCE could moderate as the company enters longer capital deployment cycles, and said they are comfortable with that if the investments strengthen the long-term growth engine.

Takeaways

Neuland’s FY26 performance was shaped by CMS scale-up, with Q4 showing the upside of a concentrated, shipment-driven CDMO model. The same model also explains why management continues to caution against reading too much into any single quarter.

The next leg of the story, as positioned by management, depends on execution in two areas: improving cash conversion through working capital discipline, and building differentiated capabilities through peptides and a larger R and D platform. The company is explicit that visibility exists in the near term through commercial and near-commercial molecules, while the peptide and R and D investments are intended to expand the addressable opportunity set over a longer horizon.